Valuation: CSL Limited

Capitalization 5.89TCr 5.02TCr 4.69TCr 4.41TCr 8.11TCr 5,33500Cr 8.86TCr 55TCr 21TCr 2,51500Cr 22TCr 22TCr 9,17900Cr P/E ratio 2026 *
23.3x
P/E ratio 2027 * 17x
Enterprise value 6.77TCr 5.77TCr 5.38TCr 5.06TCr 9.32TCr 6,12800Cr 10TCr 63TCr 24TCr 2,88900Cr 25TCr 25TCr 10,54400Cr EV / Sales 2026 *
4.23x
EV / Sales 2027 * 3.99x
Free-Float
99.9%
Yield 2026 *
2.53%
Yield 2027 * 2.75%
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.94%
1 week-1.77%
Current month-2.20%
1 month+0.22%
3 months-10.89%
6 months-23.79%
Current year-35.29%
More quotes
1 week 178.12
Extreme 178.12
186.5
1 month 175.77
Extreme 175.77
188.67
Current year 168
Extreme 168
290.32
1 year 168
Extreme 168
290.32
3 years 168
Extreme 168
314.28
5 years 168
Extreme 168
319.78
10 years 91.62
Extreme 91.62
342.75
More quotes
Manager TitleAgeSince
Chief Executive Officer 59 06/03/2023
Director of Finance/CFO 51 07/10/2025
Chief Tech/Sci/R&D Officer 63 01/10/2020
Director TitleAgeSince
Director/Board Member 71 17/10/2018
Director/Board Member 69 14/08/2013
Director/Board Member 67 16/02/2016
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.85%-1.77%-34.17%-39.12% 5.89TCr
-0.74%+3.19%+1.37%-0.84% 7.61TCr
+1.38%+69.20%+69.20%+69.20% 5.3TCr
-2.24%-4.93%+30.25%+221.80% 5.25TCr
+0.93%-3.97%+16.04%-40.22% 2.55TCr
+1.85%-7.39%+127.81%+163.37% 1.88TCr
-0.72%-6.94%+39.18%+15.08% 1.87TCr
-4.52%-5.15%+36.59%+1,036.48% 1.57TCr
+1.46%+2.05%+173.37%+704.60% 1.45TCr
-0.04%-.--%+58.82%+142.19% 1.4TCr
Average -0.36%-1.97%+51.85%+227.25% 3.48TCr
Weighted average by Cap. -0.46%-0.70%+31.05%+125.70%
See all sector performances

Financials

2026 *2027 *
Net sales 1.6TCr 1.36TCr 1.27TCr 1.2TCr 2.2TCr 1,44900Cr 2.41TCr 15TCr 5.76TCr 68TCr 6TCr 5.88TCr 2,49300Cr 1.67TCr 1.43TCr 1.33TCr 1.25TCr 2.3TCr 1,51600Cr 2.52TCr 15TCr 6.02TCr 71TCr 6.28TCr 6.15TCr 2,60800Cr
Net income 257.86Cr 219.65Cr 205.15Cr 192.88Cr 354.96Cr 23TCr 387.8Cr 2.39TCr 927.37Cr 11TCr 967.61Cr 946.9Cr 40TCr 343.13Cr 292.3Cr 272.99Cr 256.66Cr 472.36Cr 31TCr 516.05Cr 3.18TCr 1.23TCr 15TCr 1.29TCr 1.26TCr 53TCr
Net Debt 876.03Cr 746.24Cr 696.96Cr 655.27Cr 1.21TCr 79TCr 1.32TCr 8.11TCr 3.15TCr 37TCr 3.29TCr 3.22TCr 1,36500Cr 784.82Cr 668.54Cr 624.39Cr 587.04Cr 1.08TCr 71TCr 1.18TCr 7.26TCr 2.82TCr 34TCr 2.95TCr 2.88TCr 1,22300Cr
More financial data * Estimated data
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Employees
29,904
More about the company
Date Price Change Volume
15/25/15 182.12 $ -0.99% 56,209
12/25/12 183.93 $ +2.86% 9,73,901
11/25/11 178.81 $ -1.55% 8,55,310
10/25/10 181.63 $ -0.10% 6,93,730
09/25/09 181.82 $ -1.98% 8,78,270

Delayed Quote Australian S.E., December 15, 2025 at 04:44 am IST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
122.14USD
Average target price
160.40USD
Spread / Average Target
+31.33%
Consensus

Quarterly revenue - Rate of surprise